PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 23 December 2024, 07:00 am CET / 01:00 am ET alfapump® is the first US approved active implantable medical device (Class III) for the treatment of recurrent or refractory ascites due to liver cirrhosis PMA Approval and FDA Breakthrough Device Designation US market opportunity estimated at over $2...Read More